与比梅奇祖马布相关的不良事件的不成比例分析:基于FDA不良事件报告系统 (FAERS) 数据库的现实研究
Xiaojuan Lin1, Liwei Guo2, Tian Lin3,4
1Department of Pharmacy, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, China.
Naunyn-Schmiedeberg's archives of pharmacology
|December 11, 2025
概括
作为一种治疗炎症疾病的比梅基祖马布 (bimekizumab) 显示出预期的副作用,如角膜炎和新的安全信号,包括感染. 持续监测对于其长期使用至关重要.
科学领域:
- 免疫学和药理学
- 药监和药物安全 药监和药物安全
背景情况:
- 比梅基祖马布是一种IL-17A和IL-17F抑制剂,用于慢性炎症疾病.
- 在大群体中长期安全数据需要进一步描述.
研究的目的:
- 为了评估b.bimekizumab的现实世界不良事件概况.
- 使用药监数据识别安全信号和时间开始模式.
主要方法:
- 美国FDA FAERS数据的回顾性不成比例分析 (2021年第三季度-2024年第四季度).
- 在超过600万份报告中,分析了2780份与比梅奇祖马布相关的不良事件报告.
主要成果:
- 在11个系统器官类别中确定了70个显著不良事件信号.
- 确认了与标签一致的事件 (注射部位疼痛,角膜炎) 和检测到29个标签外信号 (细胞炎,感染,免疫缺陷).
- 副作用的发病时间中位数为29天.
结论:
- 药监测研究证实了已知的比梅奇祖马布的安全性,并揭示了新的安全信号.
- 强调需要进行持续的营销后监测,以完善风险效益评估.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
375
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
375
Drug Products: Biologics, Biosimilars and Interchangeables
208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
Bioequivalence studies: Biowaivers
197
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
197
Hazard Ratio
543
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
543


